CLINICAL_TRIALS
ClinicalTrials.gov record update
A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01302860
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:36:38.199414+00:00
- Published At
- 2015-08-18T00:00:00+00:00
- Record Updated At
- 2017-03-29
- Results Posted At
- 2015-08-18
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Cryopyrin-associated Periodic Syndromes", "Familial Cold Autoinflammatory Syndrome", "Muckle-Wells Syndrome", "Neonatal Onset Multisystem Inflammatory Disease"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-03-29"- protocolSection.identificationModule.nctId
"NCT01302860"- protocolSection.identificationModule.officialTitle
"A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2015-08-18"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.